JP2012530755A - 医薬品 - Google Patents

医薬品 Download PDF

Info

Publication number
JP2012530755A
JP2012530755A JP2012516692A JP2012516692A JP2012530755A JP 2012530755 A JP2012530755 A JP 2012530755A JP 2012516692 A JP2012516692 A JP 2012516692A JP 2012516692 A JP2012516692 A JP 2012516692A JP 2012530755 A JP2012530755 A JP 2012530755A
Authority
JP
Japan
Prior art keywords
cytokine
pharmaceutical product
product according
influenza
cytokines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012516692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530755A5 (enExample
Inventor
グレゴリー・ストロフ
ウィルソン・ワンダーレイ
Original Assignee
ペプトセル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0910754A external-priority patent/GB0910754D0/en
Priority claimed from GB0913956A external-priority patent/GB0913956D0/en
Priority claimed from GB0920790A external-priority patent/GB0920790D0/en
Application filed by ペプトセル リミテッド filed Critical ペプトセル リミテッド
Publication of JP2012530755A publication Critical patent/JP2012530755A/ja
Publication of JP2012530755A5 publication Critical patent/JP2012530755A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012516692A 2009-06-22 2010-06-22 医薬品 Withdrawn JP2012530755A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0910754.1 2009-06-22
GB0910754A GB0910754D0 (en) 2009-06-22 2009-06-22 Pharmaceutical agent
GB0913956.9 2009-08-10
GB0913956A GB0913956D0 (en) 2009-08-10 2009-08-10 Pharmaceutical agent
GB0920790.3 2009-11-27
GB0920790A GB0920790D0 (en) 2009-11-27 2009-11-27 Pharmaceutical agent
PCT/EP2010/058788 WO2010149641A2 (en) 2009-06-22 2010-06-22 Pharmaceutical agent

Publications (2)

Publication Number Publication Date
JP2012530755A true JP2012530755A (ja) 2012-12-06
JP2012530755A5 JP2012530755A5 (enExample) 2013-06-27

Family

ID=42727542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012516692A Withdrawn JP2012530755A (ja) 2009-06-22 2010-06-22 医薬品

Country Status (10)

Country Link
US (1) US20120100155A1 (enExample)
EP (1) EP2424893A2 (enExample)
JP (1) JP2012530755A (enExample)
KR (1) KR20120044937A (enExample)
CN (1) CN102459339A (enExample)
AU (1) AU2010264764A1 (enExample)
BR (1) BRPI1013525A2 (enExample)
CA (1) CA2764257A1 (enExample)
RU (1) RU2012101995A (enExample)
WO (1) WO2010149641A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142387A1 (en) * 2012-03-19 2013-09-26 Cardiomems, Inc. Pulmonary arterial hemodynamic monitoring for chronic obstructive pulmonary disease assessment and treatment
WO2013179302A1 (en) 2012-05-15 2013-12-05 Rajesh Shah Oral anti-inflammatory formulation comprising potentised cytokine
EP2922465A4 (en) 2012-11-21 2016-07-06 Cardiomems Inc DEVICES, SYSTEMS AND METHODS FOR ASSESSING AND TREATING PULMONARY ARTERIAL HYPERTENSION (PAH)
US9198908B2 (en) 2013-03-15 2015-12-01 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) Methods for the treatment of cardiovascular conditions
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CN111214495B (zh) * 2020-03-02 2021-12-31 广西医科大学第一附属医院 注射用母牛分枝杆菌在制备用于防治呼吸系rsv感染的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462454B2 (en) * 2004-10-12 2008-12-09 Advanced Biotherapy, Inc. Treatment of herpes
RU2332236C1 (ru) * 2007-02-02 2008-08-27 Олег Ильич Эпштейн Лекарственное средство для лечения гриппа у птиц
US9598488B2 (en) * 2008-02-01 2017-03-21 Albany Medical College Blockage of interferon-gamma for prevention of polymicrobial synergy

Also Published As

Publication number Publication date
WO2010149641A2 (en) 2010-12-29
KR20120044937A (ko) 2012-05-08
AU2010264764A1 (en) 2011-12-08
EP2424893A2 (en) 2012-03-07
WO2010149641A3 (en) 2011-02-24
CA2764257A1 (en) 2010-12-29
US20120100155A1 (en) 2012-04-26
RU2012101995A (ru) 2013-07-27
BRPI1013525A2 (pt) 2016-04-05
CN102459339A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
Seys et al. New insights in neutrophilic asthma
Guabiraba et al. IL‐22 modulates IL‐17A production and controls inflammation and tissue damage in experimental dengue infection
Hanania Targeting airway inflammation in asthma: current and future therapies
Tagliabue et al. Obesity: impact of infections and response to vaccines
Olomski et al. Interleukin 31 in insect bite hypersensitivity—Alleviating clinical symptoms by active vaccination against itch
Ohara et al. Type 17 immunity: novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells
Won et al. Inhaled delivery of Interferon-lambda restricts epithelial-derived Th2 inflammation in allergic asthma
JP2012530755A (ja) 医薬品
Acciani et al. Epidermal growth factor receptor signalling regulates granulocyte–macrophage colony‐stimulating factor production by airway epithelial cells and established allergic airway disease
Holgate A look at the pathogenesis of asthma: the need for a change in direction
Almon et al. Novel orally administered recombinant anti-TNF alpha fusion protein for the treatment of ulcerative colitis: results from a phase 2a clinical trial
Ramalingam et al. Regulation of helminth-induced Th2 responses by thymic stromal lymphopoietin
Shastri et al. Interleukin-13: A pivotal target against influenza-induced exacerbation of chronic lung diseases
Gubernatorova et al. Mouse models of severe asthma for evaluation of therapeutic cytokine targeting
Walsh Targeting airway inflammation: novel therapies for the treatment of asthma
Walsh Novel therapies for asthma-advances and problems
Kirillova et al. Application of monoclonal antibody drugs in treatment of COVID-19: a review
US20090155286A1 (en) Type I interferon blocking agents for prevention and treatment of psoriasis
JP2012530755A5 (enExample)
US11826413B2 (en) Pharmaceutical composition comprising attenuated Streptococcus pneumoniae strains and use thereof
Wippel-Slupetzky et al. Future perspectives in the treatment of psoriasis
Imanirad et al. Current biologics in asthma treatment
US10286068B2 (en) Methods to improve induction of IgA antibodies by vaccines
Fiorenzo et al. Mechanisms of asthma exacerbations
Li Advances in the study of cytokine storm mechanisms in pneumonia: An example of IL-6 and IL-33

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130513

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130703